Accession Number:



Quantitative Phase Microscopy for Real-Time Clinical Determination of Drug Therapy Response in Primary and Metastatic Breast Cancer

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

University of Utah

Personal Author(s):

Report Date:


Pagination or Media Count:



There are no biomarkers that can accurately predict chemotherapy response in advanced cancer patients and less than 10 of patients with a detected targetable mutation are eligible for a clinical trial. There is a need for new diagnostic methods that can accurately stratify high-risk patients to effective, FDA-approved therapies. Our current patient-derived models for assessing tumor drug response require 1-8 months to obtain drug sensitivity profiles making these impractical for patient care. In this project we will develop a functional assay with the new capability to predict cancer cell response to therapy within 2 d of sample collection in terms of both population response and single-cell heterogeneity. In year 1 we have developed the technical platform for this work which will be applied in years 2 and 3. Overall, our project will provide real-time feedback to oncologists on drug sensitivityresistance and resistant subpopulations.


Subject Categories:

  • Medicine and Medical Research
  • Biochemistry
  • Pharmacology

Distribution Statement:

[A, Approved For Public Release]